Acomplia Rimonabant’s clinical trials
Written by admin on February 6th, 2008 in Rimonabant acomplia news.
A major study released Tuesday indicates Sanofi-Aventis’ weight-loss drug candidate Acomplia can help obese adults lose weight and keep it off for at least two years.
But some experts warned that it may be premature to call Acomplia the next big thing in the weight-loss market.
Still, the findings, which appear in the Feb. 15 issue of the Journal of the American Medical Association, could help position Acomplia as a formidable competitor to weight-loss drugs already on the market, such as Abbott’s Meridia (sibutramine) and Roche’s Xenical (orlistat).
Sanofi filed a new drug application for Acomplia with the Food and Drug Administration last year. The FDA is expected to wrap up its review of the weight-loss product in the next week or so.
The study showed that Acomplia is effective and as effective, if not a little more, than the two other drugs already approved for weight loss: sibutramine and orlistat, the study’s lead author F. Xavier Pi-Sunyer, of St. Luke’s-Roosevelt Hospital Center, told United Press International.
Acomplia Rimonabant is a drug to assist obese people to lose weight and it is approved for sale Europe and UK with prescription from 28th June 2006. Since that time, this drug acomplia rimonabant is called a miracle drug for obesity treatment.
As with most drug treatment , acomplia-rimonabant/Acomplia Rimonabant does not work for everyone. Clinical trials of this drug Acomplia Rimonabant demonstrated that 70% of patients were able to lose at least 5% of their body weight over a 12 month period. Around 39% of patients who took acomplia rimonabant managed to lose at least 10% of their bodyweight over the same period. It was also noted that most of the weight loss occurred within the first nine months of this acomplia rimonabant’s treatment.
